MedTrace Logo

Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial

NCT05046561 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 598

Last updated 2022-09-09

No results posted yet for this study

Summary

Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)

Conditions

  • Covid19

Interventions

DRUG

STRI Formula

STRI Formula is a combination of food based substances (botanicals, vitamins, minerals, and protein) with multiple, distinct, synergistic, direct and indirect antiviral effects against SARS-CoV-2

DRUG

Placebo

Placebo oral capsule

Sponsors & Collaborators

  • Eyecheck, Inc.

    lead INDUSTRY

Principal Investigators

  • Rama D Jager, MD · Eyecheck, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-04
Primary Completion
2022-12-31
Completion
2023-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05046561 on ClinicalTrials.gov